Patient-specific Immunoglobulin E (IgE) and IgE-bearing effector cell recognizing Bet v 1 and homologous tree pollen allergen (Bet v 1-IgE/FcεRI complex)

This target represents the immunological axis responsible for Type I hypersensitivity reactions to birch pollen and related allergens. It consists of patient-specific Immunoglobulin E (IgE) antibodies bound to high-affinity Fc epsilon receptors (FcεRI) on the surface of effector cells, primarily mast cells and basophils [2]. When these IgE molecules recognize and bind to Bet v 1 (the major birch pollen allergen) or its homologs, they trigger receptor cross-linking and subsequent cell degranulation [1, 4]. This event leads to the release of inflammatory mediators like histamine and leukotrienes, causing symptoms of allergic rhinitis, asthma, and pollen-food allergy syndrome [2, 5]. Therapeutic strategies targeting this complex include monoclonal antibodies like Omalizumab, which sequester free IgE to reduce receptor density on cells [3]. Additionally, allergen-specific immunotherapies and recombinant vaccines like BM41 aim to induce immune tolerance or blocking IgG antibodies that prevent the allergen from reaching the IgE-bearing effector cells [4, 5].

Other names

Bet v 1-specific IgEIgE-Fc epsilon receptor I complexBirch allergen-IgE-effector cell axisMast cell-bound IgEBasophil-bound IgE

Sequestration of circulating IgE to prevent binding to FcεRI, downregulation of surface FcεRI expression on effector cells, and induction of allergen-specific IgG4 antibodies that compete with IgE for allergen binding [2, 4, 5].